LYF Stock Chart & Stats
€0.31
€0.01(3.92%)
At close: 4:00 PM EST
€0.31
€0.01(3.92%)
Day’s Range― - ―
52-Week Range€0.23 - €0.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€129.49M
Enterprise Value€101.31
Total Cash (Recent Filing)€15.83M
Total Debt (Recent Filing)€1.39M
Price to Earnings (P/E)54.7
Beta-0.16
Next Earnings
Sep 22, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding430,333,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)1.71
Price to Sales (P/S)2.30
P/FCF Ratio14.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€642.96K
Bulls Say, Bears Say
Bulls Say
Debt ManagementThe business is now debt-free, having fully repaid all bank borrowings.
Financial PerformanceEKF reports a positive 1Q25 trading update with the business on track to meet current FY25 market expectations for revenues.
Financial StabilityThe company completed a £1m share buyback, purchasing 4.6 million shares, which reflects confidence in its financial position.
Bears Say
Revenue DeclineFY24 revenues declined 4.6%, which was lower than prior consensus.
EKF Diagnostics Holdings News
LYF FAQ
What was EKF Diagnostics Holdings PLC’s price range in the past 12 months?
EKF Diagnostics Holdings PLC lowest stock price was €0.23 and its highest was €0.34 in the past 12 months.
What is EKF Diagnostics Holdings PLC’s market cap?
EKF Diagnostics Holdings PLC’s market cap is €129.49M.
When is EKF Diagnostics Holdings PLC’s upcoming earnings report date?
EKF Diagnostics Holdings PLC’s upcoming earnings report date is Sep 22, 2026 which is in 58 days.
How were EKF Diagnostics Holdings PLC’s earnings last quarter?
EKF Diagnostics Holdings PLC released its earnings results on Mar 24, 2026. The company reported €0.007 earnings per share for the quarter, the consensus estimate of €0.007 by €0.
Is EKF Diagnostics Holdings PLC overvalued?
According to Wall Street analysts EKF Diagnostics Holdings PLC’s price is currently Overvalued.
Does EKF Diagnostics Holdings PLC pay dividends?
EKF Diagnostics Holdings PLC does not currently pay dividends.
What is EKF Diagnostics Holdings PLC’s EPS estimate?
EKF Diagnostics Holdings PLC’s EPS estimate is 0.01.
How many shares outstanding does EKF Diagnostics Holdings PLC have?
EKF Diagnostics Holdings PLC has 430,333,100 shares outstanding.
What happened to EKF Diagnostics Holdings PLC’s price movement after its last earnings report?
EKF Diagnostics Holdings PLC reported an EPS of €0.007 in its last earnings report, expectations of €0.007. Following the earnings report the stock price went down -1.493%.
Which hedge fund is a major shareholder of EKF Diagnostics Holdings PLC?
Currently, no hedge funds are holding shares in DE:LYF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EKF Diagnostics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.74%
Trailing 12-Months
Company Description
EKF Diagnostics Holdings PLC
EKF Diagnostics Holdings plc, a company founded in 1990 and based in Cardiff, United Kingdom, operates as an international supplier of diagnostic solutions. The firm excels in the development, manufacturing, and distribution of a wide array of diagnostic instruments, chemical reagents, and associated products. Its extensive market reach spans across Europe, the Middle East, the Americas, Asia, Africa, and beyond. The company's product lineup addresses various critical diagnostic needs. This includes a range of hemoglobin analysis devices, such as the handheld DiaSpect Tm and the quantitative Hemo Control. EKF also provides advanced glucose and lactate analyzers like the Biosen C-Line series, alongside point-of-care solutions for diabetes management, exemplified by the Quo-Lab A1c and Quo-Test A1c. Beyond these, their offerings extend to specialized diagnostic tools: the Creamatocrit Plus for assessing lipid concentration in mothers' milk, QuPID and True20 pregnancy tests, and the STAT-Site M Beta-hydroxybutyrate analyzer. EKF further supplies a comprehensive suite of clinical chemical analyzers and reagents, designed for monitoring conditions such as ketosis, glycated albumin, glycated serum protein, and utilizing markers like Procalcitonin for bacterial infections and sepsis. Additional provisions include immunoassay kits, general chemistry analyzers like the Altair 240, micro centrifuges, the Uri-Trak 120 urine analyzer, and dedicated kits and services for COVID-19. The company also offers its manufacturing capabilities as contract solutions to third-party businesses and delivers professional laboratory services.